IDH1 and glioma: Interestingly, in IDH1 mutant glioma, 2-HG has been shown to inhibit branched-chain amino acid transaminases BCAT1 and BCAT2, which catalyze the degradation of BCAA into glutamate, increasing the dependency on glutamine to sustain glutamate and glutathione production and leading to synergy between glutaminase inhibition with CB-839 and radiation therapy [164, 165].